New England Journal of Medicine October 28, 2021

Dual Antiplatelet Therapy after PCI in Patients at High Bleeding Risk

Marco Valgimigli, Enrico Frigoli, Dik Heg, et al.

Bottom Line

In patients at high bleeding risk who underwent percutaneous coronary intervention, abbreviating dual antiplatelet therapy to 1 month was noninferior to standard therapy for ischemic outcomes and superior for reducing major or clinically relevant nonmajor bleeding.

Key Findings

1. Net adverse clinical events (NACE), a composite of death from any cause, myocardial infarction, stroke, or major bleeding, occurred in 7.5% of the abbreviated-therapy group and 7.7% of the standard-therapy group (difference, -0.23 percentage points; 95% CI, -1.80 to 1.33; P<0.001 for noninferiority) [3.1.4].

2. Major adverse cardiac or cerebral events (MACCE), a composite of death from any cause, myocardial infarction, or stroke, occurred in 6.1% of the abbreviated-therapy group compared with 5.9% in the standard-therapy group (difference, 0.11 percentage points; 95% CI, -1.29 to 1.51; P=0.001 for noninferiority).

3. Major or clinically relevant nonmajor bleeding (BARC 2, 3, or 5) was significantly reduced with abbreviated therapy, occurring in 6.5% of patients versus 9.4% in the standard-therapy arm (difference, -2.82 percentage points; 95% CI, -4.40 to -1.24; P<0.001 for superiority).

Study Design

Design

Randomized Controlled Trial

Open-Label

Sample

4,579

Patients

Duration

335 days

Median

Setting

30 countries

Population Patients at high bleeding risk who had undergone successful percutaneous coronary intervention of all significant coronary stenoses using a biodegradable-polymer sirolimus-eluting stent and remained free from ischemic and bleeding events 30 to 44 days post-PCI.

Intervention Abbreviated DAPT: Immediate discontinuation of dual antiplatelet therapy at the time of randomization (1 month post-PCI), transitioning to single antiplatelet therapy for the remainder of the follow-up period.

Comparator Standard DAPT: Continuation of dual antiplatelet therapy for at least 2 additional months (or at least 5 additional months for patients presenting with acute coronary syndrome without an indication for oral anticoagulation), followed by single antiplatelet therapy.

Outcome Three ranked primary outcomes assessed cumulatively at 335 days: Net adverse clinical events (NACE), major adverse cardiac or cerebral events (MACCE), and major or clinically relevant nonmajor bleeding.

Study Limitations

• The open-label design introduces the potential for ascertainment bias, particularly regarding the evaluation of nonmajor bleeding endpoints.

• The trial exclusively used one specific type of biodegradable-polymer sirolimus-eluting stent (Ultimaster), which may limit the generalizability of the findings to other contemporary drug-eluting stents.

• The definition of 'standard therapy' allowed for variable durations of dual antiplatelet therapy based on clinical presentation and concomitant oral anticoagulation, introducing heterogeneity in the control arm.

• Because randomization occurred 1 month post-PCI, the findings only apply to the selected subset of patients who tolerated the initial 30 days of therapy without experiencing ischemic or bleeding complications.

Clinical Significance

The MASTER DAPT trial provides definitive prospective evidence that for high-bleeding-risk patients, continuing dual antiplatelet therapy beyond 1 month post-PCI offers no additional ischemic protection but significantly increases the risk of bleeding complications. This supports a paradigm shift toward personalized, abbreviated antithrombotic strategies in this vulnerable population.

Historical Context

Historically, the prevention of stent thrombosis following percutaneous coronary intervention mandated prolonged dual antiplatelet therapy (often 12 months or longer), a standard established during the era of first-generation drug-eluting stents. As stent technology evolved with thinner struts and biocompatible or biodegradable polymers, the risk of late stent thrombosis markedly declined. Concurrently, real-world registry data highlighted that prolonged DAPT drives substantial bleeding morbidity, particularly in elderly and medically complex patients. While earlier trials like LEADERS FREE and STOPDAPT-2 explored 1-month DAPT regimens in highly specific or lower-risk cohorts, MASTER DAPT provided robust validation in a dedicated, globally representative, all-comers high-bleeding-risk population, cementing the safety and efficacy of early DAPT discontinuation.

Guided Discussion

High-yield insights from every perspective

Med Student

Medical Student

Why is dual antiplatelet therapy (DAPT) necessary after percutaneous coronary intervention, and what physiological trade-off does the MASTER-DAPT trial highlight by shortening the duration to exactly 1 month?

Key Response

DAPT (aspirin plus a P2Y12 inhibitor) is required to prevent early stent thrombosis while the metal struts of the newly placed stent undergo endothelialization. The trade-off in shortening DAPT is balancing the risk of ischemic events (stent thrombosis or spontaneous myocardial infarction) against the iatrogenic risk of major bleeding. The trial highlights that in High Bleeding Risk (HBR) patients, newer generation stents endothelialize rapidly enough that 1 month of DAPT safely prevents thrombosis while significantly reducing bleeding compared to longer durations.

Resident

How do you define a High Bleeding Risk (HBR) patient in clinical practice, and how do the findings of the MASTER-DAPT trial challenge the traditional management of an HBR patient presenting with an Acute Coronary Syndrome (ACS)?

Key Response

HBR is typically defined using the Academic Research Consortium (ARC-HBR) criteria, which includes factors like age over 75, need for oral anticoagulation, severe chronic kidney disease, or recent major bleeding. Traditionally, an ACS presentation dictates a strict 12-month DAPT duration to prevent recurrent ischemic events. However, MASTER-DAPT included patients with both chronic and acute coronary syndromes, suggesting that even in the setting of ACS, stepping down to single antiplatelet therapy after just 1 month is a viable and safer strategy for patients meeting HBR criteria, challenging the universal 12-month ACS rule.

Fellow

In the abbreviated DAPT arm of the MASTER-DAPT trial, patients transitioned to single antiplatelet therapy (SAPT) after 1 month. What evidence dictates the choice between aspirin versus a P2Y12 inhibitor for the SAPT phase, and how does the concomitant need for oral anticoagulation (OAC) influence this decision?

Key Response

The trial left the choice of SAPT to the investigator. Emerging data (such as the HOST-EXAM trial) suggests P2Y12 monotherapy may be superior to aspirin for long-term maintenance. For patients on OAC (e.g., for atrial fibrillation), dropping aspirin early and maintaining a P2Y12 inhibitor plus OAC is strongly supported by trials like AUGUSTUS and ENTRUST-AF PCI. Fellows must synthesize these trials to recognize that for an HBR patient on an OAC, discontinuing aspirin at 1 month and continuing the OAC with a P2Y12 inhibitor is the optimal strategy to minimize bleeding without increasing ischemic risk.

Attending

Given the non-inferiority for ischemic events demonstrated in MASTER-DAPT, should 1-month DAPT become the absolute default strategy for all HBR patients, or are there specific procedural features that would compel you to override these trial results in your practice?

Key Response

While the trial establishes 1 month as an evidence-based default for the average HBR patient, attendings must exercise advanced clinical judgment regarding anatomical and procedural complexity. Complex PCI (e.g., left main stenting, complex two-stent bifurcation strategies, or stenting of the last remaining vessel) carries a catastrophic risk if stent thrombosis occurs. Although MASTER-DAPT included some complex cases, highly complex anatomy often warrants extending DAPT beyond 1 month despite HBR status, utilizing a highly individualized shared decision-making approach.

Scholarly Review

Critical appraisal through the lens of expert reviewers and guideline development

PhD

The MASTER-DAPT trial utilized a hierarchical testing strategy with three co-primary outcomes (NACE, MACCE, and bleeding). What are the statistical and methodological risks of using a composite Net Adverse Clinical Events (NACE) endpoint in a non-inferiority design, and how did the inclusion of MACCE address this limitation?

Key Response

A major statistical risk of a NACE endpoint (which combines both bleeding and ischemic events) in a non-inferiority trial is that a profound reduction in bleeding can statistically mask an unacceptable increase in ischemic events, yielding a 'non-inferior' NACE result that hides clinical harm. The investigators mitigated this by including MACCE (purely ischemic events) as a separate co-primary endpoint powered for non-inferiority. This ensures that the abbreviated DAPT strategy did not achieve non-inferiority on the NACE endpoint merely by trading a reduction in bleeding for an increase in infarctions.

Journal Editor

The MASTER-DAPT trial required patients to be free from ischemic and bleeding events for the first 30 days post-PCI before randomization occurred. How does this landmark randomization design introduce survivorship bias, and what threats to external validity should a critical reviewer flag for the readership?

Key Response

Randomizing at 30 days post-PCI means the trial systematically excluded any patient who suffered a bleed or stent thrombosis during the highest-risk early period. A reviewer must flag that this introduces survivorship bias; the trial's conclusions only apply to 'event-free survivors' of the first month. The editorial framing must explicitly state that this evidence supports stopping DAPT at 1 month only for patients who successfully tolerate the initial 30-day period without complications, and cannot be used to predict outcomes for all HBR patients at the exact time of stent implantation.

Guideline Committee

Current ACC/AHA and ESC guidelines offer 1-to-3-month DAPT for HBR patients largely as Class IIa or IIb recommendations depending on clinical presentation. Based on MASTER-DAPT, should 1-month DAPT be upgraded to a Class I recommendation (Level of Evidence A) for all HBR patients, and what specific trial limitations complicate a universal class-effect recommendation?

Key Response

MASTER-DAPT provides robust randomized controlled trial evidence (LOE A) that could justify upgrading 1-month DAPT to a stronger recommendation for HBR patients. However, the committee must consider that the trial exclusively used one specific biodegradable-polymer sirolimus-eluting stent (Ultimaster). A major caveat preventing a universal Class I recommendation across all platforms is determining whether these results demonstrate a class effect for all contemporary drug-eluting stents, or if they are uniquely dependent on the specific rapid-endothelialization profile of the proprietary stent used in the trial.

Clinical Landscape

Noteworthy Related Trials

2015

LEADERS FREE Trial

n = 2,466 · NEJM

Tested

Polymer-free biolimus-eluting stent with 1-month DAPT

Population

Patients at high bleeding risk undergoing PCI

Comparator

Bare-metal stent with 1-month DAPT

Endpoint

Composite of cardiac death, myocardial infarction, or stent thrombosis

Key result: The polymer-free drug-eluting stent was superior to the bare-metal stent with respect to both the primary safety and efficacy endpoints when used with a 1-month DAPT course.

2019

TWILIGHT Trial

n = 7,119 · NEJM

Tested

Ticagrelor monotherapy after 3 months of DAPT

Population

High-risk patients undergoing PCI

Comparator

Ticagrelor plus aspirin (continued DAPT)

Endpoint

BARC type 2, 3, or 5 bleeding

Key result: Ticagrelor monotherapy significantly reduced the incidence of clinically relevant bleeding compared to ticagrelor plus aspirin without increasing ischemic events.

2019

STOPDAPT-2 Trial

n = 3,045 · JAMA

Tested

1-month DAPT followed by clopidogrel monotherapy

Population

Patients undergoing PCI with a cobalt-chromium everolimus-eluting stent

Comparator

12-month standard DAPT

Endpoint

Composite of cardiovascular and bleeding events

Key result: 1-month DAPT was superior to 12-month DAPT for the composite endpoint, driven by a significant reduction in bleeding events.

Tailored to your role

Want this tailored to you?

Add your specialty or training stage to get role-specific takeaways and more questions.

Personalize this analysis